Most prostate cancer is slow-growing and treatable with hormone therapy that cuts off the testosterone the tumor depends on. The danger is what happens when that stops working. In a subset of patients, the cancer eventually mutates into a form that no longer needs testosterone to grow — called castration-resistant prostate cancer, or CRPC — and it's this aggressive form, prone to spreading into lymph nodes and bones, that accounts for most prostate cancer deaths. Researchers at Umeå University in Sweden, working with international collaborators, say they've found a new way to block it.
The mechanism: blocking a signal cancer cells use to invade
Published June 17 in the journal Signal Transduction and Targeted Therapy, the study describes a fully human antibody that targets a specific molecular pathway: the TGF-beta type I receptor, or TβRI. Cancer cells rely on a fragment of this receptor — released when an enzyme called ADAM17 cleaves it — to trigger a process called epithelial-to-mesenchymal transition, which is essentially the switch that lets a tumor cell stop behaving like a normal, stationary cell and start invading surrounding tissue and spreading to distant sites. The new antibody works by physically blocking that cleavage step through what researchers call steric hindrance — preventing the enzyme from reaching the receptor in the first place, rather than trying to counteract the cancer's spread after it's already underway.
Why "fully human" isn't just a technical detail
Many antibody-based cancer drugs start as antibodies developed in mice, then require extensive modification — "humanization" — to reduce the risk that a patient's immune system rejects them as foreign. Landström's team built this antibody entirely from human proteins from the start, which researchers say lowers the likely risk of adverse immune reactions and simplifies the path toward eventual clinical use. In the preclinical models tested, the antibody halted both primary tumor growth and metastatic spread — addressing the two separate problems that make CRPC so difficult to treat at once.
A collaboration built for translation, not just discovery
The project drew specifically on the SciLifeLab Drug Discovery and Development Platform, a Swedish infrastructure resource built to help move lab discoveries like this one toward actual drug candidates rather than stopping at a published finding. That's a meaningful detail: many promising cancer-biology papers never progress past the mechanism-discovery stage for lack of the drug-development expertise needed to turn a target into a testable compound.
What still has to happen before this reaches a patient
The findings are preclinical — meaning results in lab and animal models, not human patients — and the researchers themselves are explicit that further safety evaluation and regulatory assessment are required before any clinical application. That typically means expanded toxicology studies and a formal application to begin Phase 1 human trials, a process that takes years even for antibodies with strong early data. Landström's team is already looking past prostate cancer specifically: because the TβRI pathway they've targeted isn't unique to prostate tumors, they say the same antibody could potentially be tested against other solid tumors that rely on similar invasion mechanisms.